Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Acrux ( (AU:ACR) ) has provided an announcement.
Acrux Limited has entered into a Sales, Marketing, Distribution, and License Agreement with Servacure Trading W.L.L. for its Dapsone 5% Gel in Saudi Arabia. This partnership marks Acrux’s strategic geographic expansion, leveraging its US FDA approvals to penetrate new markets and enhance returns on existing investments. The agreement with Servacure, which spans ten years with renewal options, involves Servacure handling regulatory approvals and manufacturing coordination in Saudi Arabia, while paying Acrux a fixed fee per unit shipped. This move is expected to strengthen Acrux’s market presence and foster long-term relationships in the Middle East.
More about Acrux
Acrux is a specialty pharmaceutical company with a strong track record in developing and commercializing topically applied pharmaceutical products. With 25 years of experience, Acrux focuses on marketing its products through licensees worldwide, particularly in the United States. The company leverages its skilled workforce, on-site laboratories, and GMP manufacturing suite to develop affordable topical generic products. Acrux is open to collaboration and commercial partnerships for product development.
Average Trading Volume: 349,642
Technical Sentiment Signal: Sell
Current Market Cap: A$7.37M
See more insights into ACR stock on TipRanks’ Stock Analysis page.